Recombinant interferons in the management of advanced malignant melanoma. Updated review of five prospective clinical trials and long-term responders.

摘要: One hundred forty-five patients with disseminated malignant melanoma have participated in five Phase II clinical trials utilizing leukocyte A recombinant interferon (IFN-alpha 2A) (96 patients), gamma (rIFN-gamma) (29), or IFN-alpha 2A concomitant rIFN-gamma (20 patients). The overall response rate was 17%, most regressions occurring the regimens. median times to progression (1 month) and survival (6 months) were generally similar those from chemotherapeutic agents. However, a limited cohort of had complete durable partial responses even after treatment discontinued maintained at less than equal 25% starting dosage. Most objective partial, occurred nonvisceral sites, detected within 2 months beginning therapy. noteworthy sequelae these regimens predominantly constitutional, but without any obvious long-term complications. These programs can be conveniently self-administered on an outpatient basis. Although single-agent for advanced will probably not offer substantive therapeutic advance, combinations molecules other biological agents (tumor necrosis factor), biochemical modulators (difluoromethylornithine), cytotoxic (bischloroethylnitrosourea, BCNU) innovative dimensions design future investigations.